Table 2.
Clinical characteristics of Dps and NDP.
| - | - |
Dps
(Doctor Patients) |
NDP
(No-doctor Patients) |
||
| - | - | N | % | N | % |
| Total | - | 29 | 100 | 30 | 100 |
| Site of Tumor | |||||
| Breast | 10 | 34.5 | 9 | 30 | |
| Lung | 4 | 13.8 | 5 | 17 | |
| Prostate | 3 | 10.4 | 3 | 10 | |
| Melanoma | 2 | 10.4 | 4 | 13 | |
| Colon | 3 | 10.4 | 0 | 0 | |
| Ovarian | 2 | 6.9 | 2 | 6 | |
| Thyroid | 1 | 3.4 | 0 | 0 | |
| Kidney | 1 | 3,4 | 1 | 4 | |
| Stomach | 1 | 3,4 | 0 | 0 | |
| Pancreas | 1 | 3,4 | 0 | 0 | |
| Testicular | 0 | 0 | 1 | 4 | |
| Uterus | 0 | 0 | 3 | 10 | |
| Cervical | 0 | 0 | 1 | 4 | |
| Stage | I | 3 | 10.4 | 3 | 10 |
| II | 9 | 31 | 6 | 20 | |
| III | 10 | 34.5 | 9 | 30 | |
| IV | 7 | 24.1 | 12 | 40 | |
| Systemic Therapies | Chemotherapy + hormonotherapy | 13 | 44.8 | 11 | 36 |
| Chemotherapy | 3 | 10.3 | 7 | 23 | |
| Immunotherapy | 2 | 6.9 | 6 | 21 | |
| Ormonotherapy | 1 | 3.4 | 5 | 17 | |
| Target Therapy | 1 | 3.4 | 1 | 3 | |
| Local Therapies | Surgery + Radiotherapy | 18 | 62.2 | 11 | 37 |
| Surgery | 9 | 31 | 13 | 43 | |
| Local-regional therapy (TARF) | 1 | 3.4 | 0 | 0 | |
| Surgery + Local-regional Therapy (TARF) | 1 | 3.4 | 2 | 7 | |
| Radiotherapy | 0 | 0 | 4 | 13 | |